| Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair–deficient cancer: results from the phase II KEYNOTE-158 study A Marabelle, DT Le, PA Ascierto, AM Di Giacomo, A De Jesus-Acosta, ... Journal of Clinical Oncology 38 (1), 1-10, 2020 | 2691 | 2020 |
| Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort … A Marabelle, M Fakih, J Lopez, M Shah, R Shapira-Frommer, ... The Lancet Oncology 21 (10), 1353-1365, 2020 | 2067 | 2020 |
| Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial SJ Antonia, JA López-Martin, J Bendell, PA Ott, M Taylor, JP Eder, ... The Lancet Oncology 17 (7), 883-895, 2016 | 1400 | 2016 |
| Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies HC Chung, SA Piha-Paul, J Lopez-Martin, JHM Schellens, S Kao, ... Journal of Thoracic Oncology 15 (4), 618-627, 2020 | 374 | 2020 |
| Overview of the BioCreative VI chemical-protein interaction Track. M Krallinger, O Rabal, SA Akhondi, MP Pérez, J Santamaría, ... BioCreative VI Workshop, Bethesda, 2017, 141–146, 2017 | 311 | 2017 |
| Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial PY Wen, A Stein, M van den Bent, J De Greve, A Wick, FYFL de Vos, ... The lancet oncology 23 (1), 53-64, 2022 | 292 | 2022 |
| A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors E Angevin, J Tabernero, E Elez, SJ Cohen, R Bahleda, JL Van Laethem, ... Clinical Cancer Research 20 (8), 2192-2204, 2014 | 254 | 2014 |
| Nivolumab alone and with ipilimumab in previously treated metastatic urothelial carcinoma: CheckMate 032 nivolumab 1 mg/kg plus ipilimumab 3 mg/kg expansion cohort results P Sharma, A Siefker-Radtke, F de Braud, U Basso, E Calvo, P Bono, ... Journal of Clinical Oncology 37 (19), 1608-1616, 2019 | 232 | 2019 |
| Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158. HC Chung, JA Lopez-Martin, SCH Kao, WH Miller, W Ros, B Gao, ... Journal of Clinical Oncology 36 (15_suppl), 8506-8506, 2018 | 218 | 2018 |
| Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma E Angevin, JA Lopez-Martin, CC Lin, JE Gschwend, A Harzstark, ... Clinical Cancer Research 19 (5), 1257-1268, 2013 | 151 | 2013 |
| Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial J Martin-Broto, N Hindi, G Grignani, J Martinez-Trufero, A Redondo, ... Journal for immunotherapy of cancer 8 (2), e001561, 2020 | 136 | 2020 |
| Progress in the clinical development of new marine-derived anticancer compounds J Jimeno, JA Lopez-Martin, A Ruiz-Casado, MA Izquierdo, PJ Scheuer, ... Anti-cancer drugs 15 (4), 321-329, 2004 | 119 | 2004 |
| Automatic De-identification of Medical Texts in Spanish: the MEDDOCAN Track, Corpus, Guidelines, Methods and Evaluation of Results. M Marimon, A Gonzalez-Agirre, A Intxaurrondo, H Rodriguez, JL Martin, ... IberLEF@ SEPLN, 618-638, 2019 | 115 | 2019 |
| Phase I clinical and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer JM Rademaker-Lakhai, S Horenblas, W Meinhardt, E Stokvis, ... Clinical cancer research 11 (5), 1854-1862, 2005 | 110 | 2005 |
| Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies S Faivre, S Chièze, C Delbaldo, N Ady-Vago, C Guzman, L Lopez-Lazaro, ... Journal of clinical oncology 23 (31), 7871-7880, 2005 | 109 | 2005 |
| Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials A Carretero-González, D Lora, I Ghanem, J Zugazagoitia, D Castellano, ... Oncotarget 9 (9), 8706, 2018 | 102 | 2018 |
| First-in-human, first-in-child trial of autologous MSCs carrying the oncolytic virus Icovir-5 in patients with advanced tumors D Ruano, JA López-Martín, L Moreno, Á Lassaletta, F Bautista, M Andión, ... Molecular therapy 28 (4), 1033-1042, 2020 | 101 | 2020 |
| Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032. SJ Antonia, JC Bendell, MH Taylor, E Calvo, D Jaeger, FG De Braud, ... Journal of Clinical Oncology 33 (15_suppl), 7503-7503, 2015 | 100 | 2015 |
| Randomized phase II study of trabectedin and doxorubicin compared with doxorubicin alone as first-line treatment in patients with advanced soft tissue sarcomas: a Spanish group … J Martin-Broto, AL Pousa, R de Las Peñas, X García del Muro, A Gutierrez, ... Journal of Clinical Oncology 34 (19), 2294-2302, 2016 | 83 | 2016 |
| Association of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158 A Marabelle, MG Fakih, J Lopez, M Shah, R Shapira-Frommer, ... Annals of Oncology 30, v477-v478, 2019 | 82 | 2019 |
Martin Krallinger*Head of Natural Language Processing for Biomedical Information Analysis (NLP4BIA), BarcelonaDirección de correo verificada de bsc.es
